Table 2 Subgroup analysis
Subgroup category | OR rate | CR rate | RR | ||||||
|---|---|---|---|---|---|---|---|---|---|
Study, n | ORR (95% CI) | I2 (%) | Study, n | CRR (95% CI) | I2 (%) | Study, n | RR (95% CI) | I2 (%) | |
Overall | 37 | 0.84 (0.80, 0.88) | 75.76 | 37 | 0.61 (0.49, 0.73) | 97.46 | 32 | 0.21 (0.15, 0.26) | 75.73 |
Study design | |||||||||
 Clinical trial | 13 | 0.80 (0.72, 0.89) | 83.81 | 13 | 0.56 (0.32, 0.80) | 98.54 | 11 | 0.15 (0.07, 0.22) | 73.10 |
 Observational study | 24 | 0.85 (0.80, 0.89) | 69.89 | 24 | 0.64 (0.51, 0.76) | 95.79 | 21 | 0.23 (0.17, 0.30) | 72.29 |
Diagnosis | |||||||||
 AIHA | 24 | 0.79 (0.73, 0.84) | 73.20 | 24 | 0.44 (0.33, 0.55) | 93.13 | 19 | 0.28 (0.20, 0.36) | 76.36 |
 wAIHA | 8 | 0.79 (0.69, 0.90) | 75.89 | 8 | 0.49 (0.22, 0.77) | 96.27 | 7 | 0.31 (0.14, 0.47) | 82.22 |
 CAD | 5 | 0.66 (0.57, 0.76) | 45.99 | 5 | 0.14 (0.03, 0.25) | 82.57 | 4 | 0.31 (0.10, 0.53) | 81.81 |
 MAHA | 13 | 0.93 (0.89, 0.97) | 46.99 | 13 | 0.93 (0.89, 0.97) | 46.99 | 13 | 0.09 (0.05, 0.13) | 29.13 |
 TTP | 12 | 0.92 (0.88, 0.96) | 50.74 | 12 | 0.92 (0.88, 0.96) | 50.74 | 12 | 0.08 (0.04, 0.12) | 21.38 |
 HUS | 1 | 0.97 (0.88, 1.06) |  | 1 | 0.97 (0.88, 1.06) |  | 1 | 0.29 (0.05, 0.52) |  |
Dosage regimen | |||||||||
 375 mg/m2 4 weekly | 28 | 0.83 (0.78, 0.88) | 78.64 | 28 | 0.62 (0.48, 0.77) | 98.03 | 24 | 0.20 (0.14, 0.26) | 77.50 |
 Other regimen | 8 | 0.84 (0.76, 0.91) | 67.49 | 8 | 0.56 (0.45, 0.67) | 70.80 | 7 | 0.24 (0.13, 0.32) | 72.87 |
Treatment modalities of AIHA | |||||||||
 RTX alone | 14 | 0.82 (0.76, 0.88) | 72.74 | 14 | 0.44 (0.29, 0.59) | 93.22 | 12 | 0.30 (0.20, 0.40) | 78.27 |
 In combination | 10 | 0.74 (0.66, 0.81) | 59.22 | 10 | 0.45 (0.27, 0.63) | 93.70 | 7 | 0.26 (0.12, 0.39) | 76.19 |